ASH 2019 MM

Compared with intravenous (IV) administration, subcutaneous daratumumab led to similar response rates with fewer infusion-related reactions. Read More ›

In systemic amyloid light chain (AL) amyloidosis, treatment with ixazomib/dexamethasone proved more beneficial than treatment of physician’s choice, although hematologic response was not improved. Read More ›

Selinexor, pomalidomide, and dexamethasone led to high response rates in patients with multiple myeloma who were refractory to lenalidomide and had not been previously treated with pomalidomide. Read More ›

After more than 4 years of median follow-up, treatment with daratumumab, lenalidomide, and dexamethasone continues to improve progression-free survival compared with lenalidomide and dexamethasone alone in relapsed/refractory multiple myeloma, with deep and durable responses. Read More ›

Despite safety concerns related to daratumumab, a meta-analysis of 5 large randomized controlled trials showed no significant increase in treatment delays, trial discontinuation, or treatment-related deaths in patients with untreated or relapsed/refractory multiple myeloma who received the drug. Read More ›

What is Minimal Residual Disease (MRD) Negativity?
Leslie Lauersdorf breaks down what it means to be MRD negative and how she explains MRD negativity to her patients. Read More ›

Multiple Myeloma as a Chronic Disease
As multiple myeloma moves toward being considered a chronic disease, nurses and navigators have new considerations to keep in mind when treating their patients. Read More ›

Triplets versus Quads
Leslie Lauersdorf explains triplet versus quad regimens in relation to multiple myeloma. Read More ›

CAR T-Cell Data in Multiple Myeloma
Leslie Lauersdorf discusses key considerations for nurses and navigators surrounding the use of CAR T-cell therapy in multiple myeloma. Read More ›

Latest Developments in Multiple Myeloma
Leslie Lauersdorf provides an overview of some of the most exciting clinical developments in multiple myeloma based on data presented at ASH 2019. Read More ›

Page 2 of 2


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: